Long-Term Outcomes of Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals in Turkey Türkiye’de Direkt Etkili Antivirallerle Tedavi Edilen Kronik Hepatit C Hastalarının Uzun Dönem Sonuçları
Viral Hepatitis Journal, cilt.30, sa.3, ss.70-76, 2024 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 3
- Basım Tarihi: 2024
- Doi Numarası: 10.4274/vhd.galenos.2024.2024-5-2
- Dergi Adı: Viral Hepatitis Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.70-76
- Anahtar Kelimeler: Hepatitis C, hepatocellular carcinoma, cirrhosis, death, sustained virologic response
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: Direct-acting antivirals (DAA) improve clinical outcomes in chronic hepatitis C (CHC). Data about the long-term outcomes of patients with CHC treated with DAAs in Turkey. We aimed to analyze the characteristics and outcomes of patients with CHC who attended the 3-year follow-up visit after completing DAA therapy and to present their implications for clinical management and public health. Materials and Methods: This single-center, single-arm, retrospective study included adult CHC patients treated with DAA ± ribavirin and attended the year 3 follow-up visit after completing treatment. Data on patient characteristics, laboratory parameters, recurrent/relapsing hepatitis C virus (HCV) infection, cirrhosis, and hepatocellular carcinoma (HCC) were collected from the hospital medical records and descriptively analyzed. Results: Sixty-eight patients (55.9% women), including 15 patients (22.1%) of foreign origin, were included in the study. Forty-six patients (67.6%) had a known route of HCV transmission, and 27 (58.7%) were infected through blood transfusion and/or surgical intervention. Most participants (57.4%) were infected with HCV genotype (GT) 1b: all patients of European origin with GT1b, two-thirds of Syrian participants with GT4, and half of Asians with GT3. Three patients had cirrhosis (4.4%; all compensated) at baseline. No patient developed relapse, reinfection, cirrhosis, decompensation, or HCC. Conclusion: Sustained virologic response, absence of new cases of cirrhosis, decompensation, or HCC during follow-up support the long-term clinical effectiveness of DAAs. Hepatitis C Prevention and Control strategies should include post-treatment follow-up of patients at high risk of progression, HCC, recurrence, and relapse, and individuals who could potentially spread the infection.